First-in-human phase I/II study of a highly selective FGFR2 inhibitor 3HP-2827 in patients with advanced solid tumors harboring FGFR2 alterations.

3HP-2827 - 3H Pharma

https://www.asco.org/abstracts-presentations/262546

Jiajia Yuan; Beicheng Sun; Yingying Du; Li Enxiao; Yi He; Lin Shen; Jia Fan; Tianshu Liu; Xianglin Yuan; Haitao Zhao; Zhengbo Song; Ning Li; Yanhong Gu; Yanqiao Zhang

Apr 21, 2026